Company intelligence / Profile preview

MEDIFIC

Hwaseong-si, Gyeonggi-do, South Koreamedific.co.kr ↗

Ownership: Private
Development stage: Preclinical

Overview

MEDIFIC has not yet entered clinical trials but has developed preclinical programs focused on first-in-class anti-cancer drugs targeting CSCs and undruggable proteins. The company uses in vivo models such as GBM orthotopic xenograft mouse models for efficacy validation. It has received support from the Korea Drug Development Fund and the Ministry of SMEs and Startups of Korea for non-clinical development projects.

No published clinical results as of May 2025.

Therapeutic areas: OncologyMetabolic Disorders
Modalities: Small molecules (for undruggable targets and cancer stem cells)Exosome-based immunotherapy
Industry: Biotech

Drug pipeline

3 assets

MFC-0102

Preclinical

2 more assets in the full pipeline.

Partnerships

Joint research contracts with Korea University, Seoul National University, Chungbuk National University; MOU with KMEDI hub.

Beyond the preview

Go deeper on MEDIFIC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDIFIC.